10 completed, 3 terminated, 1 unknown, 1 withdrawn. 15 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Candidiasis, Invasive: new trials by email Literature Review of Candidiasis, Invasive trials Research Report on Candidiasis, Invasive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia Interferon Gamma-1B - Candidemia | Phase 2 | Completed | Radboud University Medical Center | 65 | 2022-03-31 | 2026-06-22 |
| Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis Amphotericin B cholesteryl sulfate complex for injection(ABCD) - Invasive Candidiasis, Invasive Aspergillosis | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 60 | 2020-01-01 | 2020-01-13 |
| An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris APX001 - Candidemia, Invasive Candidiases | Phase 2 | Completed | Basilea Pharmaceutica | 9 | 2019-12-13 | 2025-09-16 |
| An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia APX001 - Candidemia | Phase 2 | Completed | Basilea Pharmaceutica | 21 | 2018-10-03 | 2025-09-16 |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension CD101, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 207 | 2016-07-26 | 2020-12-08 |
| Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis Micafungin - Candidiasis, Systemic, Candida Meningitis | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 35 | 2015-05-30 | 2024-11-18 |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis SCY-078, Fluconazole, Micafungin - Mycoses, Candidiasis, Invasive | Phase 2 | Completed | Scynexis, Inc. | 27 | 2014-09-01 | 2024-06-25 |
| Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064) Caspofungin, Amphotericin B Deoxycholate - Candidiasis, Invasive | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 51 | 2014-01-15 | 2019-11-25 |
| Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067) Caspofungin acetate, Placebo - Invasive Candidiasis | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 15 | 2010-12-01 | 2017-03-24 |
| A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074) Caspofungin - Candidiasis, Esophageal, Candidiasis, Invasive | Phase 2 | Completed | Merck Sharp & Dohme LLC | 20 | 2010-07-06 | 2018-08-27 |
| Anidulafungin in Patients With Hematologic Malignancies Anidulafungin - Hematologic Malignancies | Phase 2 | Terminated | Elisabethinen Hospital | 10 | 2009-10-01 | 2012-03-02 |
| Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection voriconazole (Vfend) - Candidiasis, Candidemia | Phase 2 | Completed | Pfizer | 40 | 2008-12-01 | 2011-01-28 |
| A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia hLF1-11, Placebo - Candidaemia | Phase 1 / Phase 2 | Withdrawn | AM-Pharma | 2008-07-01 | 2015-06-30 | |
| The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis. Anidulafungin, VER002 - Candidiasis | Phase 2 | Completed | Pfizer | 120 | 2001-08-01 | 2008-10-21 |
| Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis FK463 - Candidiasis | Phase 2 | Completed | Astellas Pharma Inc | 75 | 1999-02-27 | 2018-01-10 |
Candidemia (9) · Candidiasis (6) · Mycoses (3) · Aspergillosis (1) · Fungemia (1) · Hematologic Neoplasms (1) · Invasive Fungal Infections (1) · Torulopsis (1)
Bacterial Infections and Mycoses (15) · Infections (15) · Invasive Fungal Infections (14) · Mycoses (12) · Candidiasis (9) · Inflammation (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Sepsis (9) · Systemic Inflammatory Response Syndrome (9) · Fungemia (8) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Neoplasms (1)
Caspofungin (4) · Micafungin (3) · Anidulafungin (2) · Fluconazole (2) · Amphotericin B (1) · Injections (1) · Saline Solution (1) · Voriconazole (1) · amphotericin B, deoxycholate drug combination (1) · ibrexafungerp (1) · interferon gamma-1b (1) · lactoferrin (1-11), human (1)
Merck Sharp & Dohme LLC (3) · Basilea Pharmaceutica (2) · Pfizer (2) · AM-Pharma (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Elisabethinen Hospital (1) · Radboud University Medical Center (1) · Scynexis, Inc. (1)
United States (6) · Germany (4) · Italy (3) · Spain (3) · Austria (2) · Belgium (2) · Greece (2) · Netherlands (2) · Romania (2) · Bulgaria (1) · Canada (1) · El Salvador (1) · France (1) · Guatemala (1) · Honduras (1)
Marc Engelhardt (2) · David Angulo, MD (1) · Michael Girschikofsky, MD (1) · Professor P.E. Verweij, MD, PhD (1) · Taylor Sandison, MD MPH (1)
PMID 25701307, PMID 31586424, PMID 32955088, PMID 33558294, PMID 37022196, PMID 37596890, PMID 38008099, PMID 38502709, PMID 39468640, PMID 39529079, PMID 41940006
2009 (1), 2014 (1), 2015 (1)